Evaluating the Effectiveness of LACTOFOS in Constipated Patients (COSI)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Determine the effectiveness of symbiotic LACTOFOS containing FOS and probiotics against placebo in patients with a diagnosis of constipation, comparing the average number of weekly evacuations in 2 (two) groups for 30 days.
| Condition | Intervention | Phase |
|---|---|---|
|
Constipation |
Dietary Supplement: Symbiotic Lactofos Dietary Supplement: Maltodextrin |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Randomized, Double Blind, Comparative LACTOFOS With Placebo in Constipation Patients. |
- Frequency of stool - Chart [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]30 days taking 2 times per day. At morning and night
| Estimated Enrollment: | 60 |
| Study Start Date: | August 2010 |
| Estimated Study Completion Date: | August 2011 |
| Estimated Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: symbiotic |
Dietary Supplement: Symbiotic Lactofos
Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day
Other Names:
|
| Placebo Comparator: placebo |
Dietary Supplement: Maltodextrin
Maltodextrin
Other Name: Maltodextrin
|
Detailed Description:
A prospective, randomized, double blind, parallel group. Consist of a period of 30 days of treatment with placebo or with LACTOFOS.Will study 120 patients were female with a diagnosis of constipation according to Rome III criteria for at least 3 (three) months.
The experimental group (N = 60)will receive LACTOFOS 12g/day in two doses of 6 g. The control group (N = 60)will receive a placebo (maltodextrin) from 12g/day in two shots of 6 g.
Subsequently, the patients will be classified according to the study of AGACHAN, which determined a score based on the main complaints of patients. The symptoms that included evaluation for the total score were stool frequency, difficulty / straining, pain at defecation, feeling of incomplete evacuation, abdominal pain, time taken to initiate the evacuation, type of assistance for evacuation, failed attempts / day and duration of constipation. The intensity of each symptom varied within the range of 0 to 4, with the exception of the item type of assistance for evacuation, which ranged from 0 to 2.
Constipation is classified as mild when the total sum of values (scores) vary from 00 to 10, as moderate when the sum of the values obtained vary from 11 to 20 and severe when the final sum range from 21 to 30.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Females aged 18-75 years
- A diagnosis of constipation defined by Rome III criteria
- Ability to good communication with the investigator and agreeing to requests from the entire study
- Patients must sign a formal consent to participate
Exclusion Criteria:
- Constipation drug source
- History or evidence of organic disease of the gastrointestinal tract such as tumors, inflammatory bowel disease, etc.. proven by radiological or endoscopic examination of the bowel (five years before and after onset of symptoms). If the investigator has doubts should request the necessary procedures, such as sigmoidoscopy, colonoscopy or edema bariatric to exclude organic disease
- History of laxative use which in the opinion of the investigator is consistent with severe laxative dependence
- Current History recent (12 months) of significant abuse of alcohol or drugs
- History of malignancy in 5 (five) previous years (except basal cell carcinoma treated well or cervical carcinoma in situ)
- Known history of cardiovascular control inappropriate and / or significant respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other illness which compromises the ability of patients to participate in the full study
- Use of investigational drugs in the previous month or intentional use of such drugs during the study
- Intention of regular use of other medications that affect intestinal motility and / or perceived
- Lactose malabsorption is not treatable. If clinical suspicion of lactose intolerance, the procedure for proper diagnosis should be made to establish or exclude a diagnosis. If malabsorption is diagnosed, the patient should receive appropriate conditions of treatment
Contacts and Locations| Contact: Luciana Logullo | 55-11-32846318 | pesquisa@ganep.com.br |
| Contact: Dan Waitzberg, phd | 55-11-72662040 | pesquisa@ganep.com.br |
| Brazil | |
| Ganep Nutrição Humana | Recruiting |
| São Paulo, Brazil, 01323-001 | |
| Contact: Luciana C. Logullo 55-11-32846318 pesquisa@ganep.com.br | |
| Principal Investigator: Dan L. Waitzberg | |
| Sub-Investigator: Luciana C. Logullo | |
| Sub-Investigator: Maria de Lourdes T. Silva | |
| Sub-Investigator: Juliana R. Martins | |
| Sub-Investigator: Gláucia M. Shiroma | |
| Sub-Investigator: Amanda F. Bittencourt | |
| Principal Investigator: | Dan L. Waitzberg, phd | University of São Paulo |
More Information
No publications provided by University of Sao Paulo
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | SKL Functional Nutrition |
| ClinicalTrials.gov Identifier: | NCT01286376 History of Changes |
| Other Study ID Numbers: | COSI |
| Study First Received: | January 20, 2011 |
| Last Updated: | January 28, 2011 |
| Health Authority: | Brazil: Ethics Committee |
Keywords provided by University of Sao Paulo:
|
Symbiotics Fiber Constipation |
Additional relevant MeSH terms:
|
Constipation Signs and Symptoms, Digestive Signs and Symptoms |
ClinicalTrials.gov processed this record on May 19, 2013